ecancermedicalscience

Research

Is there a role for 'modified VAD' in the treatment of multiple myeloma?

4 Jun 2009
A Agazzi, S Sammassimo, D Laszlo, SJ Liptrott, R Cascio, A Alietti, C Rabascio, P Mancuso, G Pruneri, G Martinelli

VAD, (Vincristine, Doxorubicin and Dexamethasone) was initially proposed as a salvage therapy for myeloma patients in whom prior alkylating agent therapy failed, although in recent years VAD has been surpassed by novel combination therapies with new biological agents such as thalidomide (and its derivative, lenalidomide) and bortezomib. After the excellent results obtained by the novel agents, VAD can no longer be proposed in preparation to autologous transplantation, although there are still indications that VAD remains useful and clinically relevant in the initial treatment of symptomatic multiple myeloma.

Related Articles

Bennani Mechita Nada, Messaoud Sara, Elboukhari Elmamoun Yousra, Amina Kili, El Khorassani Mohammed, Lakhrissi Mariam, Isfaoun Zineb, El Ansari Naoual, Razine Rachid, Obtel Majdouline, El Kababri Maria, Hessissen Laila
Ally H Mwanga, Erick M Mbuguje, Jeanine Justiniano, Balowa Musa, Nashivai Kivuyo, Daniel W Kitua, Eva Uiso, Andrew Swallow, Edith Kimambo, Azza Naif, Deogratius B Mwanakulya, Swaleh Pazi, Advera Ngaiza, Seif Wibonela, Behnam Shaygi, Cameron E Gaskill
Sasongko Hadi Priyono, Winardi Budiwinata, Budianto Tedjowitono, Effendy, Muhamad Daffa Ibnurasy Pratama